Coverage
AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.
AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.
AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.
AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.
AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.
AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.
Filings
| Filing | Date |
|---|---|
| Tagrisso recommended for EU approval - LAURA | 18 Nov 2024 |
| Director/PDMR Shareholding | 15 Nov 2024 |
| Director/PDMR Shareholding | 15 Nov 2024 |
| Director/PDMR Shareholding | 13 Nov 2024 |
| Dato-DXd new BLA submitted, NSQ BLA withdrawn | 12 Nov 2024 |
| 9M and Q3 2024 Results | 12 Nov 2024 |
| KOMET Phase III trial met primary endpoint | 12 Nov 2024 |
| AstraZeneca invests $3.5 billion in US | 12 Nov 2024 |
| Tezspire nasal polyps trial met primary endpoints | 8 Nov 2024 |
| AZN share price movement | 5 Nov 2024 |
| Total Voting Rights | 1 Nov 2024 |
| AZN China President under investigation | 30 Oct 2024 |